ArticleJournal of cellular and molecular medicine2025
Exploring the Value of sC5b-9 in the Diagnosis of Haematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy in Children.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.Blood advances · 2026Article
- Exploring the Value of sC5b-9 in the Diagnosis of Haematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy in Children.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to explore the association between plasma human terminal complement complex C5b-9 (sC5b-9) levels and the occurrence of haematopoietic stem cell transplantation-associated thrombotic microangiopathy (TA-TMA) in children. The study retrospectively analysed the data of 131 patients who underwent allogeneic haematopoietic stem cell transplantation (allo-HSCT) at the Department of Haematology-Oncology between May 2020 and July 2023. The clinical data included dynamic data on plasma sC5b-9 concentrations and analysed the potential of pre- and post-transplantation levels for the prediction and diagnosis of TA-TMA after allo-HSCT. The median age of the cohort was 5.9 [3.4, 10.8] years, and it comprised 73 (55.8%) male and 58 (44.2%) female patients. The primary diseases were haematologic malignancy in 57 cases (43.5%), aplastic anaemia in 39 cases (29.8%) and Mediterranean anaemia in 13 cases (9.9%). Out of the 131 patients, 21 (14.7%) developed TA-TMA, and the median time of onset was 88 [59, 136] days after transplantation. The 1-year overall survival rate was significantly higher in the non-TA-TMA group (92.7% ± 2.5%) than in the TA-TMA group (47.6% ± 10.7%) (χ
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.